Articles Referencing KBIO
KaloBios Pharma Incurs Wider Loss - Analyst Blog
4/3/2013, 1:22 pm from Zacks.com in Investing, Business, Stocks
KaloBios Pharmaceuticals, Inc. ( KBIO ) reported a net
loss per share of $11.22 in 2012, wider than the Zacks Consensus
Estimate of a loss of $5.69 and the year-ago loss of $1.15. Revenues... Read >>
Weekly recap: Most January pricings since 2006, Zoetis surges in debut
2/1/2013, 5:13 pm from Renaissance Capital in News Headlines, IPOs
After last week's five deals, January finished the month with 12
pricings, making it the second most active January in the past
decade, trailing only the 15 pricings in January 2006.... Read >>
KaloBios prices upsized deal at $8, at low end of the range
1/31/2013, 8:09 am from Renaissance Capital in News Headlines, IPOs
KaloBios Pharmaceuticals, which is developing monoclonal
antibodies to treat respiratory diseases and cancer, raised $70
million by offering 8.8 million shares (500,000 more than expected)
at... Read >>
KaloBios revises IPO terms; lowers range, increases shares offered
1/30/2013, 12:53 pm from Renaissance Capital in News Headlines, IPOs
KaloBios Pharmaceuticals, which is developing monoclonal
antibodies to treat respiratory diseases and cancer, revised the
proposed deal size for its upcoming IPO on Wednesday. The South... Read >>
5 US IPOs planned for the week of Jan 28
1/28/2013, 7:00 am from Renaissance Capital in News Headlines, IPOs
The following IPOs are expected to price this week : Gladstone Land ( LAND ), a externally
managed REIT planning to acquire agricultural real estate, plans to
raise $50 million by... Read >>
Therapeutic biopharma KaloBios sets terms for $50 million IPO
1/15/2013, 3:35 pm from Renaissance Capital in News Headlines, IPOs
KaloBios, a biopharmaceutical company focused on therapeutics
that treat respiratory diseases and cancer, announced terms for its
IPO on Tuesday. The South San Francisco, CA-based company plans... Read >>
KaloBios files for a $60 million IPO
10/5/2012, 11:44 am from Renaissance Capital in News Headlines, IPOs
KaloBios, a biopharmaceutical focused on therapeutics that treat
respiratory diseases and cancer, filed on Friday with the SEC to
raise up to $60 million in an initial public offering. The... Read >>